Derivation (group A) | Validation (group B) | |||
---|---|---|---|---|
n | RA | n | RA | |
Age (years, mean ± SD) | 87 | 56.1 ± 13.8 | 88 | 57.3 ± 14.2 |
Female (%) | 87 | 64 (73.6) | 88 | 66 (75) |
Serology n (%) | ||||
CCP positive | 74 | 52 (70.3) | 78 | 57 (73.1) |
RF positive | 82 | 48 (58.5) | 85 | 53 (62.4) |
CRPb (mg/L) | 63 | 10.91 ± 22.73 | 74 | 7.24 ± 11.86 |
Tobacco n (%) | 85 | 22 (25.9) | 82 | 19 (23.5) |
Disease duration (years) | 88 | 11.6 ± 5.8 | 89 | 10.3 ± 6.1 |
Active diseasea n (%) | 81 | 42 (51.9) | 82 | 37 (45.1) |
RAPID-3 scoresc | 71 | 27 (38) | 67 | 24 (35.8) |
Erosions | 82 | 27 (32.9) | 84 | 25 (29.8) |
Subcutaneous nodules | 84 | 11 (13.1) | 88 | 9 (10.2) |
ILDd | 87 | 4 (4.6) | 89 | 3 (3.4) |
Current treatment n (%) | ||||
Biologics | 86 | 36 (41.9) | 85 | 33 (38.8) |
DMARDe | 85 | 78 (91.8) | 86 | 78 (90.7) |
Prednisone > 5 mg | 85 | 6 (7.1) | 85 | 7 (8.2) |
Biologics ever | 84 | 42 (50) | 85 | 41 (48.2) |